Efficacy and plasma concentrations of indinavir when boosted with ritonavir in human immunodeficiency virus-infected Thai children

Pediatric Infectious Disease Journal

Volumn 26, Issue 1, 2007, Pages 86-88

  Plipat, Nottasorn ^a   Cressey, Tim R ^b   Vanprapar, Nirun ^a   Chokephaibulkit, Kulkanya ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Children; Drug levels; Indinavir; Pharmacokinetics; Thailand

Indexed keywords

INDINAVIR; RITONAVIR;

ARTICLE; CHILD; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; FEMALE; GEOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; DRUG SYNERGISM; FEMALE; HIV INFECTIONS; HUMANS; INDINAVIR; MALE; RITONAVIR; THAILAND;

EID: 33846004830     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000247140.94669.1b     Document Type: Article

References (11)

1. Cressey TR, Leenasirimakul P, Jourdain G, et al. Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability. J Antimicrob Chemother. 2005;55:1041-1044.
2. Boyd M, Mootsikapun P, Burger D, et al. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antivir Ther. 2005;10:301-307.
3. Bergshoeff AS, Fraaij PL, van Rossum AM, et al. Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children. Antimicrob Agents Chemother. 2004;48:1904-1907.
4. Chadwick EG, Rodman JH, Samson P, et al. Antiviral activity, tolerance and pharmacokinetics of indinavir with two doses of ritonavir as salvage therapy in children [abstract]. 10th Conf Retrovir Opportunistic Infect. 2003;abstr 875.
5. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guideline for the use of antiretroviral agents in pediatric HIV infection [Centers for Disease Control and Prevention web site]. Available at: http://aidsinfo.nih.gov/guidelines/pediatric/PED_032405.pdf. Accessed October 19, 2005.
6. Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analog scale. HIV Clin Trials. 2004;5:74-79.
7. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit. 2003;25:393-399.
8. Burger DM, Hoetelmans RM, Hugen PW, et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther. 1998;3:215-220.
9. Burger D, Boyd M, Duncombe C, et al. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother. 2003;51:1231-1238.
10. Executive Summary: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 2001;285:2486-2513.
11. Lapphra K, Vanprapar N, Phongsamart W, Chearskul P, Chokephaibulkit K. Dyslipidemia and lipodystrophy in HIV-infected Thai children on highly active antiretroviral therapy (HAART). J Med Assoc Thai. 2005;88:956-966.